Revolution Medicines (NASDAQ:RVMD) Releases Earnings Results, Beats Estimates By $0.05 EPS

Revolution Medicines (NASDAQ:RVMD) released its earnings results on Wednesday. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05, Briefing.com reports. During the same period last year, the company posted ($0.72) earnings per share. Revolution Medicines’s revenue was down 100.0% on a year-over-year basis.

Revolution Medicines Price Performance

RVMD stock traded down $0.52 during trading on Thursday, reaching $37.79. 733,087 shares of the company were exchanged, compared to its average volume of 1,344,738. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -10.16 and a beta of 1.46. Revolution Medicines has a twelve month low of $15.44 and a twelve month high of $40.21. The company has a 50-day moving average of $33.59 and a two-hundred day moving average of $28.45.

Insider Buying and Selling at Revolution Medicines

In related news, CFO Jack Anders sold 10,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total value of $400,300.00. Following the sale, the chief financial officer now owns 101,959 shares of the company’s stock, valued at $4,081,418.77. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CFO Jack Anders sold 10,000 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total transaction of $400,300.00. Following the completion of the sale, the chief financial officer now directly owns 101,959 shares in the company, valued at $4,081,418.77. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Jeff Cislini sold 1,500 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $30.99, for a total value of $46,485.00. Following the completion of the transaction, the general counsel now directly owns 54,374 shares in the company, valued at $1,685,050.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,705 shares of company stock worth $1,031,049. 8.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

RVMD has been the subject of a number of recent analyst reports. Wedbush increased their price target on shares of Revolution Medicines from $42.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday. Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Revolution Medicines in a research report on Thursday. Oppenheimer lifted their price target on shares of Revolution Medicines from $43.00 to $45.00 and gave the company an “outperform” rating in a research report on Friday, April 12th. Piper Sandler started coverage on Revolution Medicines in a research note on Monday, March 11th. They set an “overweight” rating and a $43.00 price objective on the stock. Finally, Raymond James upgraded Revolution Medicines from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $36.00 to $48.00 in a research report on Wednesday, April 10th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $41.60.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.